{
  "denotations": [
    {
      "id": "T1",
      "obj": "Disease",
      "span": {
        "begin": 64,
        "end": 72
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 80,
        "end": 84
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 179,
        "end": 185
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 189,
        "end": 194
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 214,
        "end": 228
      }
    },
    {
      "id": "T11",
      "obj": "Chemical",
      "span": {
        "begin": 158,
        "end": 172
      }
    },
    {
      "id": "T10",
      "obj": "Chemical",
      "span": {
        "begin": 253,
        "end": 260
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "19273354_4",
  "text": "An aetiological approach has identified monogenic patients with diabetes due to TCF1 mutations who are particularly sensitive to the hypoglycaemic effects of sulphonylureas , and KCNJ11 or ABCC8 mutations in which sulphonylureas can be used in place of insulin treatment ."
}
